Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Clinical trial Open access

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

K. Ikezawa T. Imai R. Takada Takuo Yamai N. Fukutake M. Urabe Yugo Kai Kaori Mukai T. Nakabori K. Ohkawa
Sep 2026 · Cancer Reports · Vol 9 · 0 citations · 46 references
Medicine

TL;DR

Biweekly gemcitabine plus nab‐paclitaxel plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains limited.

Abstract

Although older adults (≥ 75 years) constitute a large proportion of patients with unresectable pancreatic cancer (PC), they remain underrepresented in clinical trials. Biweekly gemcitabine plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains limited.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Sep 2026

PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy...

Zhen-Yan Wang, Yan Wang · 1 citation
Open access Sep 2026

Real‐World Outcomes of Weekly Paclitaxel–Carboplatin‐Based Chemoradiotherapy Versus Cisplatin‐Based Chemoradiotherapy for FIGO Stage IB2–IVA Cervical cancer: A Retrospective Observational Study

We compared outcomes and toxicities of weekly paclitaxel plus carboplatin‐based (wTC) and cisplatin‐based (CDDP) concurrent chemoradiotherapy (CCRT) in FIGO stage IB2–IVA cervical cancer cases.

Ayano Shimizu, K. Chikazawa, Y. Fukuda et al. · 0 citations
Review Open access Sep 2026

Sintilimab Combined With Albumin‐Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review

For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD‐1 inhibitor with albumin‐bound paclitaxel and S‐1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in sel...

Yu-Fan Tang, Bo-Quan Zhou, B.-B. Wen et al. · 0 citations
Review Open access Oct 2026

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies

Simple Summary Platinum-resistant ovarian cancer (PROC) is no longer managed only with sequential single-agent chemotherapy. Randomized phase III trials now support pembrolizumab plus weekly paclitaxel with or without bevacizumab, mirvetuximab soravtansine for FRα-high disease, and relacorilant plus nab-paclitaxel, whi...

Seiji Mabuchi, Ai Kusakabe, Y. Takimoto · 0 citations
Open access Sep 2026

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER...

Xiao-Pei Dong, Fan Li, Yang Yuan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.